Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP-94253 is a potent and selective serotonin 5-HT1B receptor agonist, belonging to the tetrahydropyridinylpyrrolopyridine chemical family[1][3]. It exhibits high selectivity for the 5-HT1B receptor over closely related receptors such as 5-HT1D and 5-HT1A[1][3]. In animal studies, CP-94253 has been shown to promote wakefulness by increasing dopamine release, reduce food intake and promote satiety, enhance the reinforcing effects of cocaine, and may have antidepressant-like effects[1][13]. It also attenuates cocaine-seeking behavior and reduces cocaine intake after abstinence, suggesting potential utility in treating substance use disorders[1][10]. CP-94253 is used primarily in preclinical research and is not approved for therapeutic use in humans[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cp-94253.